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AbstrAct
Introduction Evidence exists that unblinded randomised 
clinical trials (RCTs) overestimate intervention effects 
compared with blinded RCTs. It has been suggested that 
this is less pronounced for objective (ie, not subject to 
interpretation) outcome measures, including mortality. 
This may not apply in the intensive care unit (ICU), as most 
deaths are preceded by decisions to withhold or withdraw 
treatments. Lack of blinding of physicians in RCTs of 
ICU interventions may potentially influence the decision 
towards a higher threshold for discontinuing treatment in 
patients who receive the investigational treatment and/or 
a lower threshold for discontinuing treatment in patients 
who receive the comparator (control). This may have 
important implications for patients, caregivers, researchers 
and society. Accordingly, we aim to assess whether lack of 
blinding affects mortality effect estimates in RCTs of ICU 
interventions.
Methods and analysis We will conduct a systematic 
review with meta-analyses and assess the effect of 
blinding versus no blinding on mortality effect estimates in 
RCTs of interventions used in adult ICU patients. We will 
systematically search the Cochrane Library for systematic 
reviews reporting mortality effect estimates of any 
intervention used in adult ICU patients which includes at 
least one RCT with ‘low risk of bias’ in the bias domains 
‘blinding of participants and personnel’ and/or ‘blinding 
of outcome assessment’ and one RCT with ‘unclear’ or 
‘high risk of bias’ in the same bias domain(s). For each 
intervention, we will compare summary mortality effect 
estimates in blinded versus unblinded trials.
Ethics and dissemination This research does not require 
ethical approval as we will use summary data from trials 
already approved by relevant ethical institutions. We 
will report the results in accordance with the Preferred 
Reporting Items for Systematic Review and Meta-Analysis 
(PRISMA) statement and submit the final paper to an 
international peer-reviewed journal.
Trial registration number PROSPERO, registration 
number: CRD42017056212.
IntroductIon
description of the condition
Randomised clinical trials (RCTs) and 
systematic reviews of these represent the 
gold standard for the assessment of benefits 
and harms of healthcare interventions.1 The 
validity of effect estimates of interventions 
in RCTs, and therefore in systematic reviews, 
depends on different aspects of the study 
design, each affecting the risk of bias.1 2 These 
aspects include random sequence generation, 
allocation concealment, blinding of partic-
ipants and personnel, blinding of outcome 
assessment, incomplete outcome data, selec-
tive reporting of trial results and other risks 
of bias.1 2 Bias can be defined as systematic 
errors in results or inferences that favour one 
outcome over others.1 The impact of bias on 
trial results varies as some are insignificant 
while others may be substantial and drive 
most, if not all, of the observed intervention 
effect.2 The direction in which a certain bias 
operates is usually unknown and may differ 
between trials; in one trial, bias may lead to 
overestimation of the intervention effect 
whereas the same bias may lead to underesti-
mation in another.2
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Protocol
Strengths and limitations of this study
 ► This protocol for a systematic review has been 
prepared in accordance with the Cochrane 
Handbook and the Preferred Reporting Items for 
Systematic Review and Meta-Analysis Protocols 
(PRISMA-P) statement.
 ► A predefined statistical analysis plan, including 
sensitivity analyses, is presented.
 ► Duplicate, independent literature search and data 
extraction will be performed.
 ► Not all high-quality randomised clinical trials of 
interventions used in the intensive care unit may 
have been included in a Cochrane review.
 ► ‘High risk of bias’ in the domains ‘blinding of 
participants and personnel’ and ‘blinding of outcome 
assessment’ may be associated with ‘high risk of 
bias’ in other bias domains.
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Empirical evidence from meta-epidemiological studies 
based on collections of meta-analyses implies that RCTs 
with ‘high risk of bias’ due to study design flaws tend 
to exaggerate intervention effects compared with trials 
with ‘low risk of bias’.3–7 It seems that trials reporting 
inadequate or unclear randomisation sequence and/or 
allocation concealment exaggerate intervention effects 
estimates compared with trials reporting adequate 
measures in these design aspects.3 5–7 Similarly, RCTs with 
inadequate or unclear blinding also overestimate benefits 
of an intervention and underestimate harms, compared 
with RCTs with adequate blinding.3–7
description of the intervention
Blinding is considered a critical component of modern 
medical research methodology and most researchers 
worldwide are familiar with the general concept. However, 
confusion exists regarding terminology and definitions.8 9 
In RCTs, ‘blinding’ refers to techniques applied to keep 
participants, healthcare and trial personnel including 
physicians, investigators, data collectors, outcome asses-
sors and statisticians unaware of the treatment allocation 
throughout the trial.1 8 10 11
Blinding can be applied in many different ways 
depending on the clinical setting and the intervention 
assessed. In trials assessing pharmacological interven-
tions, blinding of participants and healthcare and trial 
personnel are often achieved with the use of placebo.8 
Although blinding is notoriously harder to incorporate 
and maintain in non-pharmacological trials (eg, in surgical 
trials due to different incisions and scars between the 
groups),12 it is possible (eg, by using placebo dressings).13 
In both pharmacological and non-pharmacological 
RCTs, blinding of statisticians can be accomplished using 
independent personnel (without knowledge of treatment 
allocation) and applying non-identifying terms to the 
groups before performing statistical analyses (eg, groups 
A and B).14
In some cases, blinding is not feasible or ethically 
justifiable. For instance, in trials comparing surgical 
with medicinal or no interventions, participants may 
sometimes only be blinded using ethically questionable 
methods like sham surgery.15 Furthermore, surgeons who 
perform the intervention are often impossible to blind. 
In these cases, blinding of other trial personnel (eg, 
personnel involved in postoperative care and outcome 
assessment) may reduce the risk of bias associated with 
inadequate blinding of trial participants and personnel.14
How the intervention might work
Blinding of participants and healthcare and trial 
personnel in RCTs aims to minimise the risk of perfor-
mance bias and detection bias.2 Performance bias is 
the bias associated with unequal management of patients 
in the care provided (co-interventions) and unequal 
exposure to factors other than the intervention investi-
gated.2 16 If unblinded, the participants’ expectations 
about a ‘new and exciting’ intervention or a ‘mediocre’ 
standard intervention may affect the psychological or 
physical response.11 In addition, the knowledge of the 
intervention assignment could be important for the 
participants’ corporation; participants who believe they 
have been assigned to an inferior intervention may be 
less likely to comply with the trial protocol, more likely 
to seek additional treatment outside the trial and more 
likely to leave the trial resulting in loss to follow-up (attri-
tion bias).8 14 17 If trial personnel are unblinded, their 
inclinations about the investigated treatment may be 
directly transferred to the participants18 and knowledge 
of the intervention assignment may, whether conscious or 
unconscious, prompt differential use of co-interventions 
(supplemental care, interventions and diagnostic proce-
dures) across the intervention groups.2 8 11
Blinding of data collectors and outcome assessors 
reduces the risk of detection bias. Detection bias or ascer-
tainment bias refers to differential outcome assessment 
between the intervention groups.16 If data collectors and 
outcome assessors are unblinded, preconceived opinions 
regarding the intervention may influence the assessment; 
if outcome assessors believe the tested intervention is 
superior they may assess outcomes more generously in 
participants receiving that particular intervention and 
vice versa.19 Lack of blinding of statisticians may also intro-
duce bias through selective use and reporting of statistical 
tests, and they should, therefore, remain blinded until all 
data analyses have been completed.14
Why it is important to do this review
The impact of blinding on effect estimates appears to 
depend on the outcome of interest. Subjective outcomes 
(eg, postoperative pain) seem highly vulnerable to the 
blinding status, whereas objective (ie, not subject to 
interpretation) outcomes including mortality may be less 
affected.3 6 However, this may not be true in the ICU since 
almost 80% of deaths are preceded by a decision to with-
hold or withdraw treatments.20 Lack of adequate blinding 
of healthcare personnel, including ICU physicians, in 
RCTs of intensive care interventions may potentially influ-
ence this decision in the direction of a higher threshold 
for discontinuing treatment in patients receiving the 
experimental intervention and/or a lower threshold 
for discontinuing treatment in patients receiving the 
comparator (control). Hence, there is a risk that inade-
quately blinded RCTs of ICU interventions overestimate 
benefit and underestimate harm even if mortality is the 
outcome.3
Recommendations for clinical practice are now 
commonly issued in accordance with the Grading of 
Recommendations Assessment, Development and Eval-
uation (GRADE) methodology.21 The confidence in the 
effect estimate of any intervention is the most important 
determinant of the overall assessment of the quality of 
evidence.22 23 An incorrect assumption of ‘low risk of bias’ 
where the outcome in question is death maytherefore 
result in unwarranted recommendations of potentially 
harmful interventions.24 25 This may have important 
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implications for patients, caregivers, researchers and 
society.
objectIves
We aim to assess the effect of blinding of participants, 
healthcare and trial personnel and outcome assessment 
on mortality effect estimates in RCTs of interventions 
used in adult ICU patients.
Research question: does blinding of participants, 
healthcare and trial personnel and outcome assessment 
affect mortality effect estimates in RCTs of interventions 
used in adult ICU patients compared with no blinding?
MetHods and analysIs
study design
We will conduct a systematic review and meta-analyses in 
accordance with the recommendations by the Cochrane 
Collaboration where applicable.2
study registration
This protocol has been prepared in accordance with the 
Preferred Reporting Items for Systematic Review and 
Meta-Analysis Protocols (PRISMA-P) guidelines (check-
list is included as online supplementary file 1).26 27 The 
review has been registered in the Prospective Register 
of Systematic Reviews (PROSPERO); registration 
number CRD42017056212; available from http://www. 
crd. york. ac. uk/ PROSPERO/ display_ record. asp? ID= 
CRD42017056212.
criteria for considering studies for this review
Types of studies
We will include parallel group RCTs as follows: first, we 
will identify relevant Cochrane reviews using the search 
strategy described below and assess them for eligibility 
(full text). All inclusion criteria must be fulfilled: (1) 
population: adult patients in the ICU, (2) intervention: 
any intervention used in the ICU, (3) outcome: mortality 
(reported as primary or secondary outcome) and (4) 
comprise at least one RCT with ‘low risk of bias’ in the 
bias domains ‘blinding of participants and personnel’ 
and/or ‘blinding of outcome assessment’ and one RCT 
assessing the same intervention with ‘unclear’ or ‘high 
risk of bias’ in the same bias domain(s), as assessed by the 
Cochrane review authors. If only one blinding domain 
has been assessed, the review must comprise at least one 
RCT with and without ‘low risk of bias’ in that domain. 
Second, RCTs included in the eligible Cochrane reviews 
will be used for the data synthesis (for study flow chart, 
see online  supplementary file 2).
We will use the same restrictions on language, publica-
tion status, time frame and inclusion of unpublished data 
as done in the individual Cochrane reviews.
Quasi-randomised trials, cluster randomised trials and 
cross-over trials will be excluded along with parallel group 
RCTs not fulfilling inclusion criteria 1–3 as outlined 
above.
Types of participants
Adult patients admitted to the ICU regardless of diagnosis 
or condition. We will exclude trials including children as 
defined in the Cochrane reviews.
Types of interventions
Intervention: RCTs assessing ICU interventions with 
adequate blinding defined as ‘low risk of bias’ in the 
bias domains ‘blinding of participants and personnel’ 
and ‘blinding of outcome assessment’, as assessed by the 
Cochrane review authors.
Control: RCTs assessing ICU interventions with inade-
quate blinding defined as ‘unclear’ or ‘high risk of bias’ in 
the bias domains ‘blinding of participants and personnel’ 
and/or ‘blinding of outcome assessment’, as assessed by 
the Cochrane review authors.
types of outcome measures
Primary outcome
 ► Mortality at longest follow-up, as reported in the 
primary publication.
Secondary outcomes
 ► In-hospital mortality.
 ► In-ICU mortality.
search methods for identification of studies
We will conduct an electronic search in the Cochrane 
Library (http:// onlinelibrary. wiley. com/ cochraneli-
brary/ search) using the search string (title, abstract and 
keywords): ‘critically ill’ or ‘ICU’ or ‘intensive care’. The 
search will be limited to Cochrane reviews. No language 
or date limits will be imposed. Cochrane reviews are 
updated regularly to account of emerging evidence, and 
we will use the most recently updated review if more than 
one review on the same topic exists.
Before submission of the final draft of the manuscript 
to an international peer-reviewed journal, we will perform 
an updated search. If we identify new Cochrane reviews 
that comply with the inclusion criteria (see above), we will 
evaluate the RCTs included and incorporate the data into 
our analyses before submission of the final draft of the 
manuscript.
data collection and analysis
Selection of studies
Two members (CTA and AG) of the review group will 
independently search the Cochrane Library and iden-
tify systematic reviews eligible for inclusion (see above). 
A third author (MHM) will arbitrate disagreements. If 
consensus is not achieved, we will contact study authors 
for clarification. We will use Covidence (https://www. 
covidence. org) to manage search records and document 
reasons for trial exclusion.
Data extraction and management
Duplicate, independent data extraction will be performed 
by two members (CTA and AG) of the review group using 
a predefined electronic case report form. Disagreements 
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will be resolved through discussion with a third author 
(MHM). We will extract preaggregated data from the 
Cochrane reviews on trial characteristics (country, year 
of publication, population, intervention, comparator, 
outcome, single centre or multicentre, sample size), risk 
of bias (random sequence generation, allocation conceal-
ment, blinding of participants and personnel, blinding of 
outcome assessment, incomplete outcome data, selective 
reporting and other possible sources of bias including 
baseline imbalance, early stopping, bias due to vested 
financial interest and academic bias) as assessed by the 
Cochrane review authors and effect estimates (summary 
data for each intervention group (2×2 table): number of 
participants allocated to each intervention group and 
number of deaths in each group (mortality at longest 
follow-up, in-hospital mortality and in-ICU mortality)). 
If the data of interest is not reported (eg, assessment 
time point not specified) in the Cochrane review, we will 
consult the original publications in full text. We will not 
be blinded to author, institution or publication source of 
trials.
Assessment of risk of bias in included studies
We will use the risk of bias assessments performed by 
the Cochrane review authors according to the Cochrane 
Handbook2 for each included RCT in the following 
domains: random sequence generation, allocation 
concealment, blinding of participants and personnel, 
blinding of outcome assessment, incomplete outcome 
data, selective reporting and other bias including baseline 
imbalance, early stopping, bias due to vested financial 
interest and academic bias. For each intervention defined 
in the Cochrane reviews, the risk of bias assessments will 
be summarised in ‘risk of bias summary’ figures in trials 
with and without ‘low risk of bias’ in the bias domains 
‘blinding of participants and personnel’ and ‘blinding 
of outcome assessment’ to allow an easy review of the 
distribution of risk of bias in the included bias domains 
between adequately and inadequately blinded trials.
Measures of treatment effect
For each ICU intervention defined and assessed in the 
eligible Cochrane reviews, the included RCTs will be 
divided into subgroups with and without ‘low risk of 
bias’ in the bias domains ‘blinding of participants and 
personnel’ and ‘blinding of outcome assessment’. We 
will provide effect estimates (risk ratios and 95% CI) on 
mortality for each RCT along with summary effect esti-
mates for each of the subgroups. We will use χ2 test to test 
whether the subgroup summary effect estimates differ 
between adequately blinded (‘low risk of bias’ in both 
domains) versus unblinded trials (‘unclear’ or ‘high risk 
of bias’ in at least one domain); test of interaction. Results 
will be presented as forest plots for each intervention.
Dealing with missing data
We will not contact authors of RCTs for missing outcome 
data, as we expect that this have been done in the original 
Cochrane reviews. If the Cochrane reviews report addi-
tional outcome data (eg, if authors of a RCT were 
contacted for additional information), we will use and 
report these data to increase data completeness.
Assessment of heterogeneity
We will graphically evaluate forest plots for signs of hetero-
geneity and use D-squared and I-squared to describe 
statistical heterogeneity among the included trials. We 
will use both a fixed effect model and a random effects 
model, and will report the most conservative estimate.
Assessment of reporting bias
For each intervention (defined in the Cochrane reviews), 
we will assess reporting bias in blinded and unblinded 
trials separately by inspecting funnel plots. This assess-
ment will only be feasible if 10 or more blinded or 
unblinded trials are included.
Data synthesis
We will use Review Manager (V.5.3) as statistical software 
and consider p values <0.10 as statistically significant (test 





To assess the separate effects (if any) of risk of bias in 
the bias domains ‘blinding of participants and personnel’ 
and ‘blinding of outcome assessment’, we plan to conduct 
the following sensitivity analysis: (1) comparing mortality 
effect estimates in RCTs with ‘low risk of bias’ in the bias 
domain ‘blinding of participants and personnel’ and 
‘unclear’ or ‘high risk of bias’ in ‘blinding of outcome 
assessment’ versus RCTs with ‘unclear’ or ‘high risk of bias’ 
in both domains (sensitivity analysis 1) and (2) comparing 
mortality effect estimates in RCTs with ‘low risk of bias’ 
in the bias domain ‘blinding of outcome assessment’ and 
‘unclear’ or ‘high risk of bias’ in ‘blinding of participants 
and personnel’ versus RCTs with ‘unclear’ or ‘high risk of 
bias’ in both domains (sensitivity analysis 2).
Trials with adequate blinding (‘low risk of bias’ in the 
bias domains ‘blinding of participants and personnel’ and 
‘blinding of outcome assessment’) may be more likely to 
be of better methodological quality, including an a priori 
higher likelihood of having ‘low risk of bias’ in the other 
five bias domains.3 An unequal distribution of risk of bias 
in other bias domains between blinded and unblinded 
trials (risk of bias heterogeneity) may increase the risk of 
confounded summary estimates. To evaluate the poten-
tial confounding by unequal distributions of risk of bias, 
we will exclude RCTs with ‘unclear’ or ‘high risk of bias’ 
in the bias domains ‘random sequence generation’ and/
or “allocation concealment (sensitivity analysis 3), as risk 
of bias in these domains has been shown to influence 
intervention effect estimates markedly in large meta-ep-
idemiologic studies.3 5–7
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As separate analyses of individual interventions 
may decrease statistical power and increase the risk of 
accepting a false null-hypothesis, we also plan to conduct 
the following two sensitivity analyses: (1) compare 
mortality effect estimates of blinded versus unblinded 
RCTs by categorising the interventions into drug 
therapy, medical devices and management interventions 
(sensitivity analysis 4) and (2) compare mortality effect 
estimates of blinded versus unblinded RCTs pooling ALL 
interventions (sensitivity analysis 5).
dIscussIon
The proposed systematic review will provide important 
new information on whether blinding affects mortality 
effect estimates in RCTs of interventions used in adult 
ICU patients. The effects of ‘low risk of bias’ versus 
‘unclear’ or ‘high risk of bias’ in the bias domains 
‘blinding of trial participants and personnel’ and 
‘blinding of outcome assessment’ will be evaluated 
combined, as well as separately, to further explore the 
impact of blinding different groups in RCTs of ICU 
interventions.
The most important limitation to this study is the risk of 
confounding due to unequal distribution of risk of bias in 
the other bias domains between blinded and unblinded 
trials. To account for this, we have planned a sensitivity 
analysis in which trials without ‘low risk of bias’ in the 
bias domains ‘random sequence generation’ and ‘allo-
cation concealment’ are excluded as these two domains 
have been shown to affect intervention effect estimates 
in large meta-epidemiologic studies.3 5–7 Nonetheless, 
confounding may still arise from differences in the bias 
domains not accounted for. Another limitation may be the 
use of preaggregated data from the included Cochrane 
reviews without direct reference to the primary publi-
cations; however, we consider it sound to use data from 
Cochrane reviews, as we consider Cochrane reviews trust-
worthy. Cochrane review authors often obtain additional 
information regarding design, conduct and outcomes 
from the authors of the original papers; this may increase 
the accuracy and completeness of the data. 
Despite limitations, we believe that the results of the 
proposed systematic review will have important impli-
cations for clinical practice guideline developers, as it 
is currently standard not to consider downgrading the 
quality of evidence for lack of blinding if mortality is 
the outcome of interest.28 Recommendations based 
on overly confident effect estimates may mislead ICU 
physicians and compromise patient safety. Therefore, 




The proposed systematic review does not require ethical 
approval as it will not contain any data from any indi-
vidual person.
dissemination
We will report the results of the proposed systematic 
review in accordance with the Preferred Reporting Items 
for Systematic Review and Meta-Analysis (PRISMA) state-
ment.29 Regardless of the findings, the results will be 
published in an international peer-reviewed journal and 
presented at relevant international conferences.
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